INSIGHTS ON DRUG DEVELOPMENT

  • Tumor-Infiltrating Lymphocytes: What, Why, And How

    As we’ve begun to understand the complexities of immune mechanisms through technology, we’ve found better ways to fight disease. Here, we focus on an important player in such targeted, highly personalized cancer therapies called tumor-infiltrating lymphocytes (TILs).

  • Technology Selection For Bioavailability Enhancement

    Due to the growing incidence of low drug solubility in the pharmaceutical discovery and development pipeline, the number of enabling technologies that are employed to improve oral drug absorption and bioavailability (BA) are growing. Rational selection methodologies across this array of technologies can improve chances of clinical success, reduce program complexity, and accelerate development timelines.

  • In Vitro Test Methodologies For Characterizing Bioavailability Enhancing Formulations

    Improved methods are needed to evaluate the effectiveness of bioavailability-enhancement approaches.  This presentation covers the development of in vitro tools for characterizing bioavailability-enhancing formulations, criteria for selecting the optimal in vitro methods based on compound properties and dose, and case studies for multiple low solubility compounds.

  • High-Loaded Dosage Forms: Novel Platform Expands Dispersion Utility

    Spray-dried amorphous solid dispersions (ASDs) show enormous promise in the delivery of drug compounds with low solubility. A novel platform expands the utility of this approach to meet patient needs.

  • Lipid-Based Formulations For Early-Stage Clinical Trials

    For certain molecules, the most appropriate technology for bioavailability enhancement and accelerated development will be lipid-based formulations (LBF), supported by in silico development tools. Senior Formulation and Product Development Scientists analyze the potential benefits and applications of lipid/liquid-based formulations and how they may reduce timelines to clinical trials.

  • An Engineered Platform For High-Loaded Dosage Forms Of Amorphous Solid Dispersions

    This poster outlines a novel engineered platform for the formulation of high-active-loading oral solid dosage forms containing amorphous solid dispersions (ASDs) of a rapidly crystallizing drug with a low glass-transition temperature (Tg).

  • Combination Product Overview: Fixed Dosage

    With dwindling pipelines, limited resources, & expiring patents, now, more that ever, combination products are being considered in drug development portfolios. However, regulatory hurdles, physician acceptance, and market strategy, are just a few considerations that one should address. This brief overview will cover specifics regarding fixed dosage combinations (FDC’s), and will hopefully give your company a better understanding to the challenges ahead.

  • Formulation Selection And In Vitro Screening For Oral Bioavailability Enhancement

    Oral administration of small molecules is an ongoing challenge because most new drug candidates have poor aqueous solubility. This presentation describes use of a proven model-based technology-selection method for low-solubility molecules and in vitro evaluation strategies for three challenging classes of compounds, including one with high-dose requirements.

DRUG DEVELOPMENT SOLUTIONS

  • Surfactant Analysis Services

    Successful drug product development should integrate formulation, manufacturing process, primary packaging, device and delivery to the patient. Lonza’s Drug Product Services (DPS) offering delivers a holistic approach to DP development that anticipates and prevents problems early, and ensures the result is a product that is fit for purpose.

  • Small Molecule API Brochure

    Ensure that you always have the exact resources and expertise you need, especially for your most difficult to manufacture compounds.

  • Ibex™ Design

    The demand for biopharmaceutical products is continuously growing to serve the needs of an aging global population and the prevalence of chronic diseases. At the same time, the environment for biopharma companies is complex and challenging, with novel regulatory pathways, requirements to accelerate patient access, and rising competition.

  • Ajinomoto Bio-Pharma Services Capabilities Brochure

    Your programs deserve the most comprehensive suite of CDMO services available, and Ajinomoto Bio-Pharma Services has the Power To Make your therapeutic vision a reality — from pre-clinical through commercial production.

  • Zydis® Fast Dissolve Technologies - Effective Dose Forms For Pediatric Health

    Patient compliance with medication can be a complex problem and especially challenging  for pediatric populations.
    Zydis® fast dissolve formulations are an effective solution through extremely rapid dispersion in the mouth and the smooth, pleasant taste. Patient acceptance of Zydis formulations is especially high in paediatric populations, demonstrated by 50% of medications currently formulated in Zydis Orally Disintegrating Tablets (ODT) being specifically indicated for use with children.

INDUSTRY EVENTS